Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
annamycin + cytarabine
- Development stage
- Unknown
- Lead developer
- Moleculin Biotech
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Annamycin + cytarabine (also referred to as AnnAraC) is an investigational combination chemotherapy regimen being developed by Moleculin Biotech for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). The combination pairs liposomal Annamycin—a next-generation, non-cardiotoxic anthracycline small molecule designed to inhibit topoisomerase II and circumvent multidrug resistance—with cytarabine (Ara-C), a well-established nucleoside analog that inhibits DNA synthesis. This combination is designed to deliver synergistic anti-leukemic effects, particularly in patients who have relapsed after or are refractory to first-line induction therapies, including venetoclax-based regimens. It is currently being evaluated in the pivotal Phase 3 MIRACLE trial.
- Other names
- AnnAraCL-ANN + Ara-CL-ANN + cytarabineannamycin + Ara-Cannamycin + cytarabineliposomal annamycin + cytarabine
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on annamycin + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on annamycin + cytarabine.